Vanguard Tax Managed Fund FTSE Developed Markets ETF vs 22nd Century Group Inc — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.05, while 22nd Century Group Inc trades at $2.17 (market cap $1.62M). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| VEA | XXII | |
|---|---|---|
52-Week High | $73.79 | $594.00 |
52-Week Low | $58.90 | $2.13 |
Market Cap | — | $1.62M |
Sector | — | Technology |
Enterprise Value | — | -$2.69M |
Signals from Pluang's Aura AI — not financial advice
Vanguard FTSE Developed Markets ETF (VEA) trades at $73.46, down 0.41% on the day but near its 52-week high of $74.04. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights increased institutional buying, such as Allianz Asset Management boosting its stake by 11.8% in Q2 2026 (Defense World, 2026-09-09). The ETF offers low-cost exposure to developed international markets, with an expense ratio of 0.03% (The Motley Fool, 2026-08-20).
VEA's outlook is supported by institutional accumulation and cost efficiency, but risks include concentration in developed markets missing emerging growth. Proximity to the 52-week high suggests limited near-term upside without broader international market momentum. Investors benefit from diversification outside the U.S., though currency fluctuations and geopolitical events pose headwinds.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Trailing returns across standard periods
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →